Jupiter, Florida-based Cytonics Corporation has completed a USD 4.8 million gross-proceeds financing campaign, bringing total capital raised to USD 47 million as the clinical-stage biotechnology company advances its engineered alpha-2-macroglobulin (A2M) biologic toward a Phase Ib/IIa study in knee osteoarthritis.

The campaign drew approximately 1,500 individual investments, adding roughly 900 new investors and expanding the company's cap table to approximately 8,000 investors. Thirty-five percent of the pre-existing shareholder base reinvested during the round. Cytonics has financed itself primarily through retail channels, raising funds via Regulation A and Regulation Crowdfunding offerings rather than institutional venture capital. The company said proceeds will support continued regulatory, manufacturing, and clinical planning for the next development stage of its lead asset.

Cytonics' lead program, CYT-108, is a recombinant engineered variant of A2M designed to inhibit multiple classes of proteases implicated in cartilage degradation. The company's platform rests on the hypothesis that dysregulated protease activity is the primary molecular driver of osteoarthritis progression, and that A2M — the body's natural protease inhibitor — is present at insufficient concentrations within joints to provide therapeutic benefit. CYT-108 was engineered to increase potency against the protease classes the company said are most responsible for cartilage catabolism. Cytonics completed its Phase I first-in-human study and finalized the clinical study report in June 2026, concluding the first-in-human development stage.

Cytonics' earlier-generation autologous technology, APIC (Autologous Platelet Integrated Concentration System), which concentrates naturally occurring A2M from a patient's own blood, has been administered to more than 10,000 people and served as the clinical validation underpinning the recombinant program. The National Institutes of Health has previously supported Cytonics' research, including funding for its FACT diagnostic assay for radicular pain, with a study conducted at Stanford University.

Spot something wrong? Report an issue with this article